Trials / Terminated
TerminatedNCT05044325
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
A Two-Part First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Oral Doses of GSK3884464 in a Randomized, Double Blind, Placebo-Controlled, Dose Escalation Study in Healthy Participants
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This will be a FTIH study which aims to evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of GSK3884464 administered to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK3884464 | GSK3884464 will be administered |
| DRUG | Placebo | Placebo to match GSK3884464 will be administered. |
Timeline
- Start date
- 2021-09-20
- Primary completion
- 2022-08-05
- Completion
- 2022-08-05
- First posted
- 2021-09-14
- Last updated
- 2024-05-02
- Results posted
- 2024-05-02
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05044325. Inclusion in this directory is not an endorsement.